LMR Partners’s Agios Pharmaceuticals AGIO Stock Holding History

LMR Partners’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-5,946	Closed	-$307K	–	1096
2021 Q1	$307K	Buy	+5,946	New	+$294K	0.01%	726

Other funds holding AGIO

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LMR Partners's AGIO Position: Q2 2021 in Review

LMR Partners sold out of Agios Pharmaceuticals (AGIO) in Q2 2021, closing a stake of 5,946 shares — an estimated $307K sold.

LMR Partners first reported a position in AGIO in Q1 2021 and held it in 1 quarter. The position peaked at $307K in Q1 2021. 185 funds tracked by Wall St. Rank hold AGIO as of Q2 2021.

LMR Partners reported no remaining Agios Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
LMR Partners sold 5,946 Agios Pharmaceuticals shares in Q2 2021, an estimated $307K.
LMR Partners first reported a position in Agios Pharmaceuticals in Q1 2021 and held it in 1 quarter.
LMR Partners's Agios Pharmaceuticals position peaked at $307K in Q1 2021.
185 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2021.

Based on LMR Partners's 13F filing for Q2 2021, filed 16 Aug 2021.